comparemela.com

Latest Breaking News On - Rosetta capital - Page 10 : comparemela.com

Investegate |Schroder UK PublicPT Announcements | Schroder UK PublicPT: Immunocore Prices NASDAQ IPO

Immunocore Prices NASDAQ IPO The Company (LSE: SUPP) is pleased to announce that its portfolio company Immunocore Holdings plc ( Immunocore ) has announced the pricing of its initial public offering ( IPO ) of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an IPO price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market ( NASDAQ ) on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions.

MARKET REPORT: Reddit vs Wall Street in short-seller showdown

Schroders trust receives muted reception as it offloads ex-Woodford holdings at 20% discount

Schroders trust receives muted reception as it offloads ex-Woodford holdings at 20% discount Sale is expected to knock an additional 3.2% off NAV The Schroder UK Public Private trust has struck a deal to offload a handful of biotech stocks it inherited from Neil Woodford at a steep discount.  The £220.8m trust revealed it would be selling a basket of largely unquoted stocks to an investment fund managed by UK life sciences venture capital firm, Rosetta Capital, for £49m.   The sale price represents a 22% discount to the aggregate valuation for the holdings as at 30 September 2020 or 19% when adjusted for foreign exchange movements. 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.